Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $21.9 million.

  • Beam Therapeutics' Depreciation & Amortization (CF) rose 1.55% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 1.03%. This contributed to the annual value of $21.9 million for FY2024, which is 9.56% up from last year.
  • Latest data reveals that Beam Therapeutics reported Depreciation & Amortization (CF) of $21.9 million as of FY2024, which was up 9.56% from $20.0 million recorded in FY2023.
  • Beam Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $21.9 million during FY2024, with a 5-year trough of $4.7 million in FY2020.
  • For the 3-year period, Beam Therapeutics' Depreciation & Amortization (CF) averaged around $18.7 million, with its median value being $20.0 million (2023).
  • Data for Beam Therapeutics' Depreciation & Amortization (CF) shows a peak YoY spiked of 89.87% (in 2022) over the last 5 years.
  • Beam Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $4.7 million in 2020, then surged by 57.36% to $7.5 million in 2021, then soared by 89.87% to $14.1 million in 2022, then surged by 41.46% to $20.0 million in 2023, then climbed by 9.56% to $21.9 million in 2024.